There was a reduced relative risk in patients taking PTH therapy in one study(43) and an increased—albeit nonsignificant—risk in the other.(11) However, pooled data confirmed a nonsignificant difference in relative risk for hypocalcaemia between patients taking PTH therapy and controls (RR = 0.74; 95% CI, 0.22 to 2.51; p = 0.626); the heterogeneity between the studies was high (I2 = 82%; p = 0.018). The gene discussed is PTH; the disease is Hypocalcemia.